XENT Projected Dividend Yield

Intersect ENT, Inc. ( NASDAQ : XENT )

Intersect ENT is an ear, nose and throat medical technology company. Co.'s steroid releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL® family of products (PROPEL®, PROPEL® Mini and PROPEL® Contour) and the SINUVA® (mometasone furoate) Sinus Implant. The PROPEL family of products are used to reduce inflammation and maintain patency following sinus surgery.SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps.

20 YEAR PERFORMANCE RESULTS